Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-

Katsunori Shinozaki; Tomohiro Nishina; Junichiro Nasu; Akira Sawaki; Mototsugu Shimokawa; Yoshiyuki Yamaguchi; Michio Inukai; Takeshi Nagasaka; Hideyuki Mishima; Hiroaki Tanioka; Masazumi Okajima; Shoichi Hazama

首页> 外文期刊>BMJ Open >Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-

【24h】

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-

机译：序贯卡培他滨或5-氟尿嘧啶加贝伐单抗（Cape / 5-FU-Bmab）至卡培他滨或5-氟尿嘧啶加奥沙利铂加贝伐单抗（CapeOX / mFOLFOX6-Bmab）与CapeOX / mFOLFOX6-联合使用的随机III期临床试验方案

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstract Introduction Results from several randomised trials suggest that the sequential use of cytotoxic agents in patients with metastatic colorectal cancer (mCRC) has the potential to improve overall survival compared with combination chemotherapy. Thi

机译：摘要简介几项随机试验的结果表明，与联合化疗相比，转移性结直肠癌（mCRC）患者相继使用细胞毒剂具有改善总体生存的潜力。锡

著录项

来源
《BMJ Open》 |2016年第6期|共页
作者
Katsunori Shinozaki; Tomohiro Nishina; Junichiro Nasu; Akira Sawaki; Mototsugu Shimokawa; Yoshiyuki Yamaguchi; Michio Inukai; Takeshi Nagasaka; Hideyuki Mishima; Hiroaki Tanioka; Masazumi Okajima; Shoichi Hazama;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类临床医学;
关键词

相似文献

外文文献
中文文献

1. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6- [J] . Katsunori Shinozaki, Tomohiro Nishina, Junichiro Nasu, BMJ Open . 2016,第6期

机译：序贯卡培他滨或5-氟尿嘧啶加贝伐单抗（Cape / 5-FU-Bmab）至卡培他滨或5-氟尿嘧啶加奥沙利铂加贝伐单抗（CapeOX / mFOLFOX6-Bmab）与CapeOX / mFOLFOX6-联合使用的随机III期临床试验方案
2. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [J] . Landry Jerome C., Feng Yang, Prabhu Roshan S., The oncologist . 2015,第6期

机译：局部晚期直肠癌患者术前放开卡培他滨，奥沙利铂和贝伐单抗并发手术及术后5-氟尿嘧啶，白叶素，奥沙利铂（FOLFOX）和贝伐单抗的术前放疗的二期试验：5年临床结果ECOG-ACRIN癌症研究E3204组
3. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [J] . Jerome C. Landry, Yang Feng, Roshan S. Prabhu, The oncologist . 2015,第6期

机译：局部晚期直肠癌患者术前并发卡培他滨，奥沙利铂和贝伐单抗联合手术及术后5-氟尿嘧啶，白叶素，奥沙利铂（FOLFOX）和贝伐单抗的术前放疗的二期试验：5年临床结果E3204组
4. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study [O] . Takeshi Nagasaka, Hideyuki Mishima, Akira Sawaki, 2016

机译：卡培他滨或5-氟尿嘧啶加奥沙利铂加贝伐珠单抗（CapeOX / mFOLFOX6-Bmab）与CapeOX / mFOLFOX6-Bmab联合治疗的序贯卡培他滨或5-氟尿嘧啶+贝伐单抗（Cape / 5-FU-Bmab）随机III期临床试验方案结直肠癌的临床研究：C-cubed（C3）研究
5. Phase II Randomized Trial of Biweekly Bevacizumab, Capecitabine, Oxaliplatin and Irinotecan (BEV- CAPEOXIRI) Versus Triweekly Bevacizumab, Capecitabine and Oxaliplatin (BEV- CAPEOX) in Metastatic Colon Carcinoma [O] . ALI ABD EL-ALEEM ALI M.D., MAHMOUD ABUL-MAKAREM M.D. 2018

机译：第II期双周贝伐单抗，Capecitabine，Oxaliplatin和Irinotecan（Bev- Capeoxiri）的随机试验与转移性结肠癌的三周贝伐单抗，Capecitabine和Oxaliplatin（Bev- Capeox）相比

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-

摘要

著录项

相似文献

相关主题

期刊订阅